Clusterstock  Mar 20  Comment 
It's normal to feel uneasy about riding in an elevator.  But considering how prevalent elevators are , it's an inconvenient phobia to have.  Thankfully, deaths due to elevator accidents are extremely rare . Just in...
New York Times  Mar 20  Comment 
As officials warned of possible power failures and encouraged people to view the phenomenon only through special glasses, excitement grew for the rare celestial event.
Forbes  Mar 20  Comment 
“Art cannot exist, in the mind that won’t accept, nature at its worst.”
MarketWatch  Mar 20  Comment 
A rare total solar eclipse delivered amazing views to many in Europe Friday morning — but what lit up Twitter were jokes from those who missed out.
The Hindu Business Line  Mar 20  Comment 
A rare self-portrait by Amrita Sher-Gil has sold for US$ 2.92 million in Sotheby’s New York auction, setting a new record for an Indian woman artist. Sher-Gil’s oil-on-canvas masterpiece...
Forbes  Mar 19  Comment 
Every entrepreneur with a new technology tells me that his innovation will be industry-disrupting, meaning that it will render the existing technology obsolete, and create a new market. Yet truly disruptive innovations, like the smartphone from...  Mar 19  Comment 
CRANBURY, NJ (TheStreet) -- Amicus Therapeutics will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected -- following a successful meeting with the Food and...
NPR  Mar 19  Comment 
It's all in the timing. Biologists haven't been able to breed embryos of the rare, pillar coral in the lab because it's been tough to catch the creatures in the act.
Motley Fool  Mar 18  Comment 
The (in)famous investor's publicly traded vehicle, Icahn Enterprises, posts its first bottom-line shortfall since 2008.
MarketWatch  Mar 18  Comment 
The U.S. Food and Drug Administration approved Retrophin Inc.'s Cholbam for the treatment of rare bile acid synthesis disorders caused by single enzyme defects, the company announced on Wednesday. As a result of the approval, Retrophin will...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki